Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Downregulation of Notch Signaling in Kras-Induced Gastric Metaplasia.

Chung WC, Zhou Y, Atfi A, Xu K.

Neoplasia. 2019 Aug;21(8):810-821. doi: 10.1016/j.neo.2019.06.003. Epub 2019 Jul 2.

2.

TGIF1 functions as a tumor suppressor in pancreatic ductal adenocarcinoma.

Parajuli P, Singh P, Wang Z, Li L, Eragamreddi S, Ozkan S, Ferrigno O, Prunier C, Razzaque MS, Xu K, Atfi A.

EMBO J. 2019 Jul 1;38(13):e101067. doi: 10.15252/embj.2018101067. Epub 2019 May 31.

PMID:
31268604
3.

Anabolic effects of vitamin D and magnesium in aging bone.

Erem S, Atfi A, Razzaque MS.

J Steroid Biochem Mol Biol. 2019 Oct;193:105400. doi: 10.1016/j.jsbmb.2019.105400. Epub 2019 Jun 5. Review.

PMID:
31175968
4.

Twist1 Activation in Muscle Progenitor Cells Causes Muscle Loss Akin to Cancer Cachexia.

Parajuli P, Kumar S, Loumaye A, Singh P, Eragamreddy S, Nguyen TL, Ozkan S, Razzaque MS, Prunier C, Thissen JP, Atfi A.

Dev Cell. 2018 Jun 18;45(6):712-725.e6. doi: 10.1016/j.devcel.2018.05.026.

5.

Correction for Erker et al., "Arkadia, a Novel SUMO-Targeted Ubiquitin Ligase Involved in PML Degradation".

Erker Y, Neyret-Kahn H, Seeler JS, Dejean A, Atfi A, Levy L.

Mol Cell Biol. 2017 May 31;37(12). pii: e00193-17. doi: 10.1128/MCB.00193-17. Print 2017 Jun 15. No abstract available.

6.

Mesenchymal Stem/Stromal Cells under Stress Increase Osteosarcoma Migration and Apoptosis Resistance via Extracellular Vesicle Mediated Communication.

Vallabhaneni KC, Hassler MY, Abraham A, Whitt J, Mo YY, Atfi A, Pochampally R.

PLoS One. 2016 Nov 3;11(11):e0166027. doi: 10.1371/journal.pone.0166027. eCollection 2016.

7.

Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis.

Singh R, Gupta SC, Peng WX, Zhou N, Pochampally R, Atfi A, Watabe K, Lu Z, Mo YY.

Cell Death Dis. 2016 Jun 9;7(6):e2262. doi: 10.1038/cddis.2016.168.

8.

Dietary pterostilbene is a novel MTA1-targeted chemopreventive and therapeutic agent in prostate cancer.

Dhar S, Kumar A, Zhang L, Rimando AM, Lage JM, Lewin JR, Atfi A, Zhang X, Levenson AS.

Oncotarget. 2016 Apr 5;7(14):18469-84. doi: 10.18632/oncotarget.7841.

9.

TGIF function in oncogenic Wnt signaling.

Razzaque MS, Atfi A.

Biochim Biophys Acta. 2016 Apr;1865(2):101-4. doi: 10.1016/j.bbcan.2015.10.003. Epub 2015 Nov 11. Review.

PMID:
26522669
10.

Functional Characterization of a WWP1/Tiul1 Tumor-derived Mutant Reveals a Paradigm of Its Constitutive Activation in Human Cancer.

Courivaud T, Ferrand N, Elkhattouti A, Kumar S, Levy L, Ferrigno O, Atfi A, Prunier C.

J Biol Chem. 2015 Aug 21;290(34):21007-18. doi: 10.1074/jbc.M115.642314. Epub 2015 Jul 7.

11.

TGIF governs a feed-forward network that empowers Wnt signaling to drive mammary tumorigenesis.

Zhang MZ, Ferrigno O, Wang Z, Ohnishi M, Prunier C, Levy L, Razzaque M, Horne WC, Romero D, Tzivion G, Colland F, Baron R, Atfi A.

Cancer Cell. 2015 Apr 13;27(4):547-60. doi: 10.1016/j.ccell.2015.03.002.

12.

AKT and 14-3-3 regulate Notch4 nuclear localization.

Ramakrishnan G, Davaakhuu G, Chung WC, Zhu H, Rana A, Filipovic A, Green AR, Atfi A, Pannuti A, Miele L, Tzivion G.

Sci Rep. 2015 Mar 5;5:8782. doi: 10.1038/srep08782.

13.

Disruption of the PHRF1 Tumor Suppressor Network by PML-RARα Drives Acute Promyelocytic Leukemia Pathogenesis.

Prunier C, Zhang MZ, Kumar S, Levy L, Ferrigno O, Tzivion G, Atfi A.

Cell Rep. 2015 Feb 17;10(6):883-890. doi: 10.1016/j.celrep.2015.01.024. Epub 2015 Feb 12.

14.

Sirt2 deacetylase is a novel AKT binding partner critical for AKT activation by insulin.

Ramakrishnan G, Davaakhuu G, Kaplun L, Chung WC, Rana A, Atfi A, Miele L, Tzivion G.

J Biol Chem. 2014 Feb 28;289(9):6054-66. doi: 10.1074/jbc.M113.537266. Epub 2014 Jan 20.

15.

Identification of PHRF1 as a tumor suppressor that promotes the TGF-β cytostatic program through selective release of TGIF-driven PML inactivation.

Ettahar A, Ferrigno O, Zhang MZ, Ohnishi M, Ferrand N, Prunier C, Levy L, Bourgeade MF, Bieche I, Romero DG, Colland F, Atfi A.

Cell Rep. 2013 Aug 15;4(3):530-41. doi: 10.1016/j.celrep.2013.07.009. Epub 2013 Aug 1.

16.

Arkadia, a novel SUMO-targeted ubiquitin ligase involved in PML degradation.

Erker Y, Neyret-Kahn H, Seeler JS, Dejean A, Atfi A, Levy L.

Mol Cell Biol. 2013 Jun;33(11):2163-77. doi: 10.1128/MCB.01019-12. Epub 2013 Mar 25. Erratum in: Mol Cell Biol. 2017 May 31;37(12 ):.

17.

Ezrin ubiquitylation by the E3 ubiquitin ligase, WWP1, and consequent regulation of hepatocyte growth factor receptor activity.

Zaarour RF, Chirivino D, Del Maestro L, Daviet L, Atfi A, Louvard D, Arpin M.

PLoS One. 2012;7(5):e37490. doi: 10.1371/journal.pone.0037490. Epub 2012 May 22.

18.

Dietary and genetic evidence for enhancing glucose metabolism and reducing obesity by inhibiting klotho functions.

Ohnishi M, Kato S, Akiyoshi J, Atfi A, Razzaque MS.

FASEB J. 2011 Jun;25(6):2031-9. doi: 10.1096/fj.10-167056. Epub 2011 Mar 7.

19.

Zfp521 controls bone mass by HDAC3-dependent attenuation of Runx2 activity.

Hesse E, Saito H, Kiviranta R, Correa D, Yamana K, Neff L, Toben D, Duda G, Atfi A, Geoffroy V, Horne WC, Baron R.

J Cell Biol. 2010 Dec 27;191(7):1271-83. doi: 10.1083/jcb.201009107. Epub 2010 Dec 20.

20.

The oncoprotein c-ski functions as a direct antagonist of the transforming growth factor-{beta} type I receptor.

Ferrand N, Atfi A, Prunier C.

Cancer Res. 2010 Nov 1;70(21):8457-66. doi: 10.1158/0008-5472.CAN-09-4088. Epub 2010 Oct 19.

21.

Zfp521 is a target gene and key effector of parathyroid hormone-related peptide signaling in growth plate chondrocytes.

Correa D, Hesse E, Seriwatanachai D, Kiviranta R, Saito H, Yamana K, Neff L, Atfi A, Coillard L, Sitara D, Maeda Y, Warming S, Jenkins NA, Copeland NG, Horne WC, Lanske B, Baron R.

Dev Cell. 2010 Oct 19;19(4):533-46. doi: 10.1016/j.devcel.2010.09.008.

22.

Zinc finger protein 521, a new player in bone formation.

Hesse E, Kiviranta R, Wu M, Saito H, Yamana K, Correa D, Atfi A, Baron R.

Ann N Y Acad Sci. 2010 Mar;1192:32-7. doi: 10.1111/j.1749-6632.2009.05347.x. Review.

PMID:
20392215
23.

PTH battles TGF-beta in bone.

Atfi A, Baron R.

Nat Cell Biol. 2010 Mar;12(3):205-7. doi: 10.1038/ncb0310-205.

PMID:
20190828
24.

Repair of a segmental long bone defect in human by implantation of a novel multiple disc graft.

Hesse E, Kluge G, Atfi A, Correa D, Haasper C, Berding G, Shin HO, Viering J, Länger F, Vogt PM, Krettek C, Jagodzinski M.

Bone. 2010 May;46(5):1457-63. doi: 10.1016/j.bone.2010.02.011. Epub 2010 Feb 12.

PMID:
20153850
25.

A model of partnership co-opted by the homeodomain protein TGIF and the Itch/AIP4 ubiquitin ligase for effective execution of TNF-alpha cytotoxicity.

Demange C, Ferrand N, Prunier C, Bourgeade MF, Atfi A.

Mol Cell. 2009 Dec 25;36(6):1073-85. doi: 10.1016/j.molcel.2009.12.009.

26.

Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition.

Battaglia S, Benzoubir N, Nobilet S, Charneau P, Samuel D, Zignego AL, Atfi A, Bréchot C, Bourgeade MF.

PLoS One. 2009;4(2):e4355. doi: 10.1371/journal.pone.0004355. Epub 2009 Feb 3.

27.

The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation.

Feng SM, Muraoka-Cook RS, Hunter D, Sandahl MA, Caskey LS, Miyazawa K, Atfi A, Earp HS 3rd.

Mol Cell Biol. 2009 Feb;29(3):892-906. doi: 10.1128/MCB.00595-08. Epub 2008 Dec 1.

28.

p53 brings a new twist to the Smad signaling network.

Atfi A, Baron R.

Sci Signal. 2008 Jul 1;1(26):pe33. doi: 10.1126/scisignal.126pe33. Review.

PMID:
18594115
29.

Identification of PCTA, a TGIF antagonist that promotes PML function in TGF-beta signalling.

Faresse N, Colland F, Ferrand N, Prunier C, Bourgeade MF, Atfi A.

EMBO J. 2008 Jul 9;27(13):1804-15. doi: 10.1038/emboj.2008.109. Epub 2008 May 29.

30.

Essential role of plasminogen activator inhibitor type-1 in radiation enteropathy.

Milliat F, Sabourin JC, Tarlet G, Holler V, Deutsch E, Buard V, Tamarat R, Atfi A, Benderitter M, François A.

Am J Pathol. 2008 Mar;172(3):691-701. doi: 10.2353/ajpath.2008.070930. Epub 2008 Feb 14.

31.

The disintegrin and metalloproteinase ADAM12 contributes to TGF-beta signaling through interaction with the type II receptor.

Atfi A, Dumont E, Colland F, Bonnier D, L'helgoualc'h A, Prunier C, Ferrand N, Clément B, Wewer UM, Théret N.

J Cell Biol. 2007 Jul 16;178(2):201-8. Epub 2007 Jul 9.

32.

A mechanism for mutational inactivation of the homeodomain protein TGIF in holoprosencephaly.

Ferrand N, Demange C, Prunier C, Seo SR, Atfi A.

FASEB J. 2007 Feb;21(2):488-96. Epub 2006 Dec 8.

PMID:
17158784
33.

Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer.

Chen C, Sun X, Guo P, Dong XY, Sethi P, Zhou W, Zhou Z, Petros J, Frierson HF Jr, Vessella RL, Atfi A, Dong JT.

Oncogene. 2007 Apr 5;26(16):2386-94. Epub 2006 Oct 2.

PMID:
17016436
34.

Influence of endothelial cells on vascular smooth muscle cells phenotype after irradiation: implication in radiation-induced vascular damages.

Milliat F, François A, Isoir M, Deutsch E, Tamarat R, Tarlet G, Atfi A, Validire P, Bourhis J, Sabourin JC, Benderitter M.

Am J Pathol. 2006 Oct;169(4):1484-95.

35.

Nuclear retention of the tumor suppressor cPML by the homeodomain protein TGIF restricts TGF-beta signaling.

Seo SR, Ferrand N, Faresse N, Prunier C, Abécassis L, Pessah M, Bourgeade MF, Atfi A.

Mol Cell. 2006 Aug;23(4):547-59.

36.

Role for mitogen-activated protein kinases in phenobarbital-induced expression of cytochrome P450 2B in primary cultures of rat hepatocytes.

Joannard F, Rissel M, Gilot D, Anderson A, Orfila-Lefeuvre L, Guillouzo A, Atfi A, Lagadic-Gossmann D.

Toxicol Lett. 2006 Feb 8;161(1):61-72. Epub 2005 Sep 9.

PMID:
16154717
37.
38.

AIP4 restricts transforming growth factor-beta signaling through a ubiquitination-independent mechanism.

Lallemand F, Seo SR, Ferrand N, Pessah M, L'Hoste S, Rawadi G, Roman-Roman S, Camonis J, Atfi A.

J Biol Chem. 2005 Jul 29;280(30):27645-53. Epub 2005 Jun 8.

39.

The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation.

Seo SR, Lallemand F, Ferrand N, Pessah M, L'Hoste S, Camonis J, Atfi A.

EMBO J. 2004 Oct 1;23(19):3780-92. Epub 2004 Sep 9.

40.

Evidence for a role of MSK1 in transforming growth factor-beta-mediated responses through p38alpha and Smad signaling pathways.

Abécassis L, Rogier E, Vazquez A, Atfi A, Bourgeade MF.

J Biol Chem. 2004 Jul 16;279(29):30474-9. Epub 2004 May 7.

41.

The oncoprotein Ski acts as an antagonist of transforming growth factor-beta signaling by suppressing Smad2 phosphorylation.

Prunier C, Pessah M, Ferrand N, Seo SR, Howe P, Atfi A.

J Biol Chem. 2003 Jul 11;278(28):26249-57. Epub 2003 May 5.

42.

Evidence for a role of Smad3 and Smad2 in stabilization of the tumor-derived mutant Smad2.Q407R.

Dumont E, Lallemand F, Prunier C, Ferrand N, Guillouzo A, Clément B, Atfi A, Théret N.

J Biol Chem. 2003 Jul 4;278(27):24881-7. Epub 2003 Apr 16.

43.

Liver protection from apoptosis requires both blockage of initiator caspase activities and inhibition of ASK1/JNK pathway via glutathione S-transferase regulation.

Gilot D, Loyer P, Corlu A, Glaise D, Lagadic-Gossmann D, Atfi A, Morel F, Ichijo H, Guguen-Guillouzo C.

J Biol Chem. 2002 Dec 20;277(51):49220-9. Epub 2002 Oct 4.

44.

The expression of novH in adrenocortical cells is down-regulated by TGFbeta 1 through c-Jun in a Smad-independent manner.

Lafont J, Laurent M, Thibout H, Lallemand F, Le Bouc Y, Atfi A, Martinerie C.

J Biol Chem. 2002 Oct 25;277(43):41220-9. Epub 2002 Jul 30.

45.

Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-beta/Smad signaling.

Ferrigno O, Lallemand F, Verrecchia F, L'Hoste S, Camonis J, Atfi A, Mauviel A.

Oncogene. 2002 Jul 25;21(32):4879-84.

46.

c-Jun associates with the oncoprotein Ski and suppresses Smad2 transcriptional activity.

Pessah M, Marais J, Prunier C, Ferrand N, Lallemand F, Mauviel A, Atfi A.

J Biol Chem. 2002 Aug 9;277(32):29094-100. Epub 2002 May 28.

47.

Transforming growth factor-beta inhibition of insulin-like growth factor-binding protein-5 synthesis in skeletal muscle cells involves a c-Jun N-terminal kinase-dependent pathway.

Rousse S, Lallemand F, Montarras D, Pinset C, Mazars A, Prunier C, Atfi A, Dubois C.

J Biol Chem. 2001 Dec 14;276(50):46961-7. Epub 2001 Oct 11.

48.

Evidence for a role of the JNK cascade in Smad7-mediated apoptosis.

Mazars A, Lallemand F, Prunier C, Marais J, Ferrand N, Pessah M, Cherqui G, Atfi A.

J Biol Chem. 2001 Sep 28;276(39):36797-803. Epub 2001 Jul 26.

49.

c-Jun interacts with the corepressor TG-interacting factor (TGIF) to suppress Smad2 transcriptional activity.

Pessah M, Prunier C, Marais J, Ferrand N, Mazars A, Lallemand F, Gauthier JM, Atfi A.

Proc Natl Acad Sci U S A. 2001 May 22;98(11):6198-203.

50.

Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells.

Gallea S, Lallemand F, Atfi A, Rawadi G, Ramez V, Spinella-Jaegle S, Kawai S, Faucheu C, Huet L, Baron R, Roman-Roman S.

Bone. 2001 May;28(5):491-8.

PMID:
11344048

Supplemental Content

Support Center